Inspec

Inspec EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Inspec (6656.T) as of Oct 21, 2026 is 4.24 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 3.60 % — a change of 17.96% (higher).

EBIT/Assets

4.24 %

YoY

17.96%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Inspec is 2026 4.24 % . Operating Income to Assets Ratio (EBIT/Assets) of Inspec was 2025 3.60 % . It decreases by 17.96% higher compared to the previous year.

The Inspec EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2019
10.46 JPY
Jan 1, 2020
4.38 JPY
Jan 1, 2021
-10.29 JPY
Jan 1, 2022
0.58 JPY
Jan 1, 2023
3.41 JPY
Jan 1, 2024
-6.20 JPY
Jan 1, 2025
3.60 JPY
Jan 1, 2026
4.24 JPY
The Inspec EBIT/Assets history
YEAREBIT/AssetsYoY
4.24 %+17.96%
3.60 %-158.01%
-6.20 %-282.03%
3.41 %+490.55%
0.58 %-105.60%
-10.29 %-334.93%
4.38 %-58.13%
10.46 %-224.86%
-8.38 %-227.75%
6.56 %-806.95%
-0.93 %-117.78%
5.22 %+21.35%
4.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inspec Stock analysis

What does Inspec do? inspec Inc. generates revenue through three primary segments. The Semiconductor Package Substrates and Precision Substrate Inspection Equipment segment sells appearance inspection equipment for semiconductor package substrates and precision printed circuit boards used in smartphones, tablets, PCs, and wearable terminals. The Precision Substrate Manufacturing Equipment segment provides photoplotters, inkjet printers, and direct imaging devices along with maintenance services for printed circuit boards. The Digital Pathology Related Equipment segment develops and sells medical image processing systems, specifically whole slide imaging (WSI) for digital pathology applications. Customers include manufacturers of advanced digital devices requiring semiconductor inspection, PCB producers needing photoplotters and imaging devices, and healthcare providers utilizing whole slide imaging systems for pathology diagnostics. The company's products target the semiconductor, electronics manufacturing, and medical imaging sectors with specific applications in device assembly, PCB production, and medical diagnostics. inspec Inc. focuses on equipment for semiconductor package substrates, precision substrates, and digital pathology, serving clients in the electronics and healthcare industries. The firm's inspection and imaging solutions are tailored to meet the quality control needs of high-tech manufacturing and medical diagnostics, with no mention of additional revenue streams beyond these three segments. Inspec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inspec stock

Operating Income to Assets Ratio (EBIT/Assets) of Inspec is 4.24 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of Inspec changed from 3.60 % to 4.24 %, representing a 17.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Inspec since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Inspec with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Inspec

All Key Metrics — Inspec